Form 4: Director John LaMattina Receives Equity Grant at Ligand

Ligand Pharmaceuticals director John L. LaMattina was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Summary

• Director John L. LaMattina acquired 836 restricted stock units (RSUs) on June 5, 2026.
• The director was also granted 2,938 non-qualified stock options with an exercise price of $237 per share.
• Both the RSUs and stock options were granted by the Board of Directors during the annual meeting.
• The equity awards are set to vest on the earlier of the next annual stockholders meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or strategic direction.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized annual compensation structure for board members.

Negatives

• Dilutive impact of new equity grants, though minor in scale.

Risks

• Market price volatility affecting the value of the granted stock options.
• Potential for future dilution if additional equity grants are issued to board members.

Future Outlook

The equity grants vest on the earlier of the next annual meeting or the first anniversary of the grant date, indicating a standard one-year retention cycle for board members.

Management Comments

• The grants were issued as part of the Board of Directors' annual meeting compensation package.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board retention and alignment with long-term shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for board compensation is consistent with peer biotech companies of similar market capitalization.
• Vesting schedules of one year are standard for non-employee director compensation in the U.S. pharmaceutical industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the RSUs and stock options on or before June 5, 2027.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Equity Compensation, Director Compensation